RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsInitiationPrice Target
RBC Capital analyst Douglas Miehm initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $14.
RBC Capital analyst Douglas Miehm initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $14.